Roche is a leading global healthcare company renowned for its commitment to advancing medical diagnostics and treatment options. The Roche Cervical Cancer Portfolio exemplifies this dedication, covering the full spectrum of cervical cancer screening, triage, and diagnostic testing. With a focus on innovation, Roche offers cutting-edge solutions, such as the cobas® HPV test, which facilitates accurate risk stratification for cervical cancer by identifying high-risk HPV genotypes. Their dual-stain triage technology, including the FDA-approved CINtec PLUS Cytology test, further enhances diagnostic precision by detecting cellular changes indicative of precancerous conditions.

Recognizing the importance of comprehensive screening, Roche continuously adapts its portfolio to align with evolving medical guidelines and practices. With their advanced diagnostic tools, Roche aims to empower healthcare providers and patients, ensuring early detection and timely intervention, ultimately improving survival rates. Committed to shaping a healthier future, Roche strives to eliminate the ambiguity in cervical cancer screening and diagnosis, making significant strides in women's health.